Free Trial

HLS Therapeutics Q3 2024 Earnings Report

HLS Therapeutics logo
C$4.27 -0.13 (-2.95%)
As of 03:59 PM Eastern

HLS Therapeutics EPS Results

Actual EPS
-C$0.20
Consensus EPS
-C$0.19
Beat/Miss
Missed by -C$0.01
One Year Ago EPS
-C$0.28

HLS Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

HLS Therapeutics Announcement Details

Quarter
Q3 2024
Time
Before Market Opens

Conference Call Resources

Remove Ads

HLS Therapeutics Earnings Headlines

Q1 Earnings Estimate for TSE:HLS Issued By Stifel Canada
FBI Warns: Wave Of Retiree Cyber Hacks Coming In 2025
Try to think back to the fall of 2008… The pandemic accelerated America's descent into a “no-cash society” by several years…
HLS Therapeutics Inc (HLS) Receives a Hold from Stifel Nicolaus
See More HLS Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like HLS Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on HLS Therapeutics and other key companies, straight to your email.

About HLS Therapeutics

HLS Therapeutics (TSE:HLS) Inc is a specialty pharmaceutical company. It is focused on the acquisition and commercialization of branded pharmaceutical products in the North American markets. The company is focused on treatment products for the central nervous system (CNS), and cardiovascular specialties. The company products include Clozaril, Absorica, Vascepa, CSAN Pronto, Trinomia and Perseris. The company earns revenue in the form of product sales and royalties, out of which product sales contribute to the majority of the revenue. The company operates in Canada, the United States and the Rest of the world.

View HLS Therapeutics Profile

More Earnings Resources from MarketBeat